Summary
The product EXEMESTANE, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN66337, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with concentrations of 12.74 mg and 10.78 mg, averaging 11.76 mg, exceeding the labeled claim of 10 mg by 17.6%.
The testing process commenced on 06 February 2023, with the sample received on 15 February 2023, and the analysis completed on 21 February 2023. While the results confirm the presence of a higher-than-labeled concentration, it is essential to consider that reseller-submitted samples may represent optimal batches, potentially differing from general market consistency. Independent third-party testing remains crucial to verify product consistency across multiple batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Exemestane
- Active Ingredient: Exemestane
- Batch Number: UN66337
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #27627
- Testing Ordered: 06 February 2023
- Sample Received: 15 February 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentrations:
- 12.74 mg
- 10.78 mg
- Average Measured Concentration: 11.76 mg
- Accuracy: 117.6% (17.6% above the label claim)
- Variance: 17.6%
Verification Details
- Verification URL: www.janoshik.com/tests/27627_FR913J3ZY541
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms that the tested product exceeds its labeled claim, suggesting a higher dose per tablet than advertised. However, since the sample was submitted and funded by the reseller Opitropin.EU, there is a possibility of selective sampling of high-quality batches. For broader product reliability, further independent testing across multiple batches is recommended.
Conclusion
The analysis of Exemestane confirms a higher-than-expected measured concentration of 11.76 mg, reflecting an overdose of 17.6%. This suggests strong quality control for this particular batch; however, the observed variance highlights the need for additional testing to ensure consistent dosing across production batches. This report aims to support educational and harm reduction efforts, enabling consumers to make informed choices.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce inherent biases; however, it still provides useful insights when critically assessed alongside independent third-party results. Consumers are encouraged to interpret this data responsibly.
